Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & more

Marleen Kok • 7 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Pembrolizumab
I-SPY KEYNOTE-522

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines neoadjuvant chemoimmunotherapy for early triple-negative breast cancer. Specifically discussed is the KEYNOTE-522 trial (NCT03036488), the I-SPY trial (NCT01042379). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Marleen Kok

Optimizing immunotherapy for triple-negative breast cancer
0:47
Optimizing immunotherapy for triple-negative breast cancer
Marleen Kok • 13 Mar 2025
Assessing who can benefit from immunotherapy in ER+ breast cancer
1:13
Assessing who can benefit from immunotherapy in ER+ breast cancer
Marleen Kok • 13 Mar 2025
Reaching a consensus on early TNBC treatment guidelines
1:32
Reaching a consensus on early TNBC treatment guidelines
Marleen Kok • 13 Mar 2025
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
1:08
St Gallen 2023: de-escalation, personalized treatment & adjuvant IO following neoadjuvant IO
Marleen Kok • 16 Mar 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals